Literature DB >> 10417205

Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.

J D Barackman1, G Ott, D T O'Hagan.   

Abstract

Immunization of mice by the intranasal route with influenza virus hemagglutinin in combination with the mutant Escherichia coli heat-labile enterotoxin R72 (LT-R72) induced significantly enhanced serum and mucosal antibodies, surpassing, in most cases, responses achieved by traditional intramuscular immunization using inactivated split influenza vaccine. Furthermore, intranasal immunization with LT-R72 induced a potent serum immunoglobulin G2a response, indicating that this adjuvant has Th1 character.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417205      PMCID: PMC96738          DOI: 10.1128/IAI.67.8.4276-4279.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

Review 1.  The immune response of humans to live and inactivated influenza vaccines.

Authors:  Y Ghendon
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

2.  Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion.

Authors:  R Johannsen; H Moser; J Hinz; H J Friesen; H Gruschkau
Journal:  Vaccine       Date:  1985-09       Impact factor: 3.641

3.  Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic.

Authors:  P A Patriarca; J A Weber; R A Parker; W N Hall; A P Kendal; D J Bregman; L B Schonberger
Journal:  JAMA       Date:  1985-02-22       Impact factor: 56.272

4.  Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital.

Authors:  T W Hoskins; J R Davies; A J Smith; C L Miller; A Allchin
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

Review 5.  Serious morbidity and mortality associated with influenza epidemics.

Authors:  W P Glezen
Journal:  Epidemiol Rev       Date:  1982       Impact factor: 6.222

6.  Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation.

Authors:  J C Hierholzer; M T Suggs; E C Hall
Journal:  Appl Microbiol       Date:  1969-11

7.  Immunoglobulin A mediation of murine nasal anti-influenza virus immunity.

Authors:  K B Renegar; P A Small
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Authors:  D C Powers; S D Sears; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  Influenza vaccination.

Authors:  M A Riddiough; J E Sisk; J C Bell
Journal:  JAMA       Date:  1983-06-17       Impact factor: 56.272

10.  The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.

Authors:  G L Barchfeld; A L Hessler; M Chen; M Pizza; R Rappuoli; G A Van Nest
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

View more
  12 in total

1.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza.

Authors:  Victor C Huber; Raelene M McKeon; Martha N Brackin; Laura A Miller; Rachael Keating; Scott A Brown; Natalia Makarova; Daniel R Perez; Gene H Macdonald; Jonathan A McCullers
Journal:  Clin Vaccine Immunol       Date:  2006-09

3.  Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.

Authors:  Diana I Albu; Agnes Jones-Trower; Amy M Woron; Kathleen Stellrecht; Christopher C Broder; Dennis W Metzger
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 4.  Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.

Authors:  Cynthia A Lemere; Edward T Spooner; Jodi F Leverone; Chica Mori; Melitza Iglesias; Jeanne K Bloom; Timothy J Seabrook
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

5.  Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.

Authors:  C Bonenfant; I Dimier-Poisson; F Velge-Roussel; D Buzoni-Gatel; G Del Giudice; R Rappuoli; D Bout
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.

Authors:  J A Neidleman; M Vajdy; M Ugozzoli; G Ott; D O'Hagan
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

7.  PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens.

Authors:  Nelson F Eng; Srinivas Garlapati; Volker Gerdts; Lorne A Babiuk; George K Mutwiri
Journal:  J Immune Based Ther Vaccines       Date:  2010-08-24

8.  Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Authors:  Gabriel Pedersen; Diane Major; Sarah Roseby; John Wood; Abdullah S Madhun; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2011-05-09       Impact factor: 4.380

9.  Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization.

Authors:  J D Barackman; G Ott; S Pine; D T O'Hagan
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

10.  Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes.

Authors:  Liulin Chen; Junming Zhu; Yuhong Li; Jie Lu; Li Gao; Huibi Xu; Mingwen Fan; Xiangliang Yang
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.